Next Article in Journal
In Vitro and In Vivo Assessment of Metabolic Drug Interaction Potential of Dutasteride with Ketoconazole
Next Article in Special Issue
Stencil Printing—A Novel Manufacturing Platform for Orodispersible Discs
Previous Article in Journal
Poloxamer Hydrogels for Biomedical Applications
Previous Article in Special Issue
Additive Manufacturing of Personalized Pharmaceutical Dosage Forms via Stereolithography

3D-Printed Solid Dispersion Drug Products

Drug Delivery Group, Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King’s College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, UK
Department of Sciences for Health Promotion and Mother-Child Care “G. D’Alessandro”, University of Palermo, 90100 Palermo, Italy
Author to whom correspondence should be addressed.
Pharmaceutics 2019, 11(12), 672;
Received: 14 October 2019 / Revised: 25 November 2019 / Accepted: 5 December 2019 / Published: 11 December 2019
(This article belongs to the Special Issue 3D Printing of Pharmaceuticals and Drug Delivery Devices)
With the well-known advantages of additive manufacturing methods such as three-dimensional (3D) printing in drug delivery, it is disappointing that only one product has been successful in achieving regulatory approval in the past few years. Further research and development is required in this area to introduce more 3D printed products into the market. Our study investigates the potential of fixed dose combination solid dispersion drug products generated via 3D printing. Two model drugs—fluorescein sodium (FS) and 5-aminosalicyclic acid (5-ASA)—were impregnated onto a polyvinyl alcohol (PVA) filament, and the influence of solvent choice in optimal drug loading as well as other influences such as the physicochemical and mechanical properties of the resultant filaments were investigated prior to development of the resultant drug products. Key outcomes of this work included the improvement of filament drug loading by one- to threefold due to solvent choice on the basis of its polarity and the generation of a 3D-printed product confirmed to be a solid dispersion fixed dose combination with the two model drugs exhibiting favourable in vitro dissolution characteristics. View Full-Text
Keywords: 3D printing; amorphous solid dispersion; additive manufacturing; poor solubility; fixed dose combination 3D printing; amorphous solid dispersion; additive manufacturing; poor solubility; fixed dose combination
Show Figures

Graphical abstract

MDPI and ACS Style

Chew, S.L.; Modica de Mohac, L.; Tolulope Raimi-Abraham, B. 3D-Printed Solid Dispersion Drug Products. Pharmaceutics 2019, 11, 672.

AMA Style

Chew SL, Modica de Mohac L, Tolulope Raimi-Abraham B. 3D-Printed Solid Dispersion Drug Products. Pharmaceutics. 2019; 11(12):672.

Chicago/Turabian Style

Chew, Suet L., Laura Modica de Mohac, and Bahijja Tolulope Raimi-Abraham. 2019. "3D-Printed Solid Dispersion Drug Products" Pharmaceutics 11, no. 12: 672.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop